对代谢疾病的多激素药物治疗方法:希望和新的挑战
Camille Allard1, Daniela Cota1, Carmelo Quarta2
1University of Bordeaux, INSERM, Neurocentre Magendie, U1215, 33000, Bordeaux, France.
Drugs
|December 21, 2023
概括
新的葡萄糖类-1 (GLP-1) 受体多活性剂对2型糖尿病和肥胖症有前途. 本综述批判性地分析了它们的好处,风险和潜在机制,以改善患者的治疗结果.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基于葡萄糖类-1 (GLP-1) 受体的多活性剂是治疗2型糖尿病和肥胖的新兴治疗方法.
- 针对多个肠道激素通路的双重和三重激动剂正在临床试验中,显示出有效性.
研究的目的:
- 批判性地分析基于GLP-1受体的多抗激素剂的益处和风险.
- 探索这些药物的潜在生物机制和潜在的不良影响.
- 研究GLP-1药理学在代谢疾病之外的新应用.
主要方法:
- 文献综述和对现有临床试验数据的批判性分析.
- 检查肠道激素相关途径的机制研究.
- 综合有关疗效,安全性和治疗潜力的当前知识.
主要成果:
- GLP-1多抗激素剂显示出对血糖控制和体重管理的显著潜力.
- 关于精确的生物机制和潜在的不良影响的知识差距仍然存在.
- 证据支持单分子双倍和三倍激动剂的疗效.
结论:
- 基于GLP-1受体的多激素剂为代谢疾病提供了有前途的治疗途径.
- 进一步的研究至关重要,以阐明机制,并减轻与多元激素治疗相关的风险.
- GLP-1药理学可能会扩展到超出当前代谢疾病目标的应用.
相关概念视频
01:24Glucagon-like Receptor Agonists
327
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
327
01:24Principles of Drug Action
6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
01:28Drug Therapy
45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
45
01:15Diabetes: Management and Pharmacotherapy
288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
01:25Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K